Loading organizations...
§ Private Profile · Singapore, Central Region, Singapore
Robotic-assisted surgical systems for prostate biopsy and treatment. FDA cleared Mona Lisa 2.0 surgical robot.
Based in Singapore, Biobot Surgical Pte Ltd develops robotic-assisted surgical systems designed for minimally invasive prostate healthcare, biopsies, and targeted treatments. The venture-backed medical device manufacturer currently produces the FDA-cleared Mona Lisa 2.0 robotic needle-positioning system, a flagship technology that has been utilized in over 25,000 clinical procedures across hospitals and specialized surgical clinics worldwide. Operating with a workforce of 21 to 50 employees, the enterprise has secured $31.7 million in total capital across three financing rounds, highlighted by a recent $18 million Series B investment. Biobot Surgical is financially backed by lead healthcare investors Tony Tan and Zig Ventures, while maintaining strategic joint ventures and development partnerships with Microport Medbot, BEBIG Medical, and SingHealth. The organization was officially founded in 2007 as a spinoff by medical researchers Chris Cheng, Henry Ho, and John Yuen.
Biobot Surgical Pte Ltd has raised $23.2M across 2 funding rounds.
Biobot Surgical Pte Ltd has raised $23.2M in total across 2 funding rounds.
Biobot Surgical Pte Ltd has raised $23.2M across 2 funding rounds. Most recently, it raised $18.0M Series B in March 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 11, 2024 | $18M Series B | Tony TAN, ZIG Ventures | — | Announced |
| Dec 7, 2023 | $5.2M Venture Round | — | ZIG Ventures | Announced |
Biobot Surgical Pte Ltd has raised $23.2M in total across 2 funding rounds.
Biobot Surgical Pte Ltd's investors include Tony Tan, ZIG Ventures.